To prevent cardiovascular complications, sometimes double and triple therapy with a vitamin K antagonist (VKA), clopidogrel and/or acetylsalicylic acid (ASA) are indicated. These combinations increase the patient’s risk of serious bleeding events. Therefore, adherence to clinical guidelines is of the utmost importance when these high-risk therapies are prescribed.
Methods:
We performed a retrospective cohort study of 238 cases in a community pharmacy that were treated with a combination of VKA, clopidogrel and/or ASA between January 2006 and December 2009. Hospital records and community pharmacy records were used to obtain the indication(s), the duration of combination therapy, the presence of risk-increasing and risk-decreasing co-medications and any relevant co-morbidities. The cardiologists’ attitudes towards the prescribing of antithrombotic combinations and their self-reported adherence to guidelines were assessed by a brief questionnaire.
Results:
We found there was no guideline-based indication for 22 of the 146 cases (14%) on ASA plus clopidogrel and 19 of the 82 cases (23%) on VKA plus ASA. Of the 238 cases given antithrombotic combination therapies, 77 (32%) were placed at an additional increased risk of serious gastrointestinal events, yet 43 (56%) of these did not receive adequate gastric protection. Out of the 19 of 60 cardiologists (32%) who responded to our questionnaire; 17 (90%) and 13 (68%) stated that a strict indication is very important when initiating therapy with ASA plus clopidogrel or ASA plus VKA, respectively.
Conclusions:
There is room to further develop adherence to guideline-based prescribing of antithrombotic combination therapies and to improve prescription of gastric protection for patients receiving these high-risk combinations.
LeendertseAJEgbertsACStokerLJ. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med2008; 168: 1890–1896.
2.
SchneeweissSHasfordJGottlerM. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: A longitudinal population-based study. Eur J Clin Pharmacol2002; 58: 285–291.
3.
HowardRLAveryAJSlavenburgS. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol2007; 63: 136–147.
4.
SchulmanSSpencerFA. Antithrombotic drugs in coronary artery disease: Risk benefit ratio and bleeding. J Thromb Haemost2010; 8: 641–650.
5.
KellerTSquizzatoAMiddeldorpS. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev2007. CD005158.
6.
BowryADBrookhartMAChoudhryNK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol2008; 101: 960–966.
7.
EikelboomJWHirshJ. Combined antiplatelet and anticoagulant therapy: Clinical benefits and risks. J Thromb Haemost2007; 5 Suppl 1: 255–263.
8.
RubboliADiPG. Triple therapy of warfarin, aspirin and a thienopyridine for patients treated with vitamin K antagonists undergoing coronary stenting. A review of the evidence. Intern Emerg Med2007; 2: 177–181.
9.
SorensenRHansenMLAbildstromSZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. Lancet2009; 374: 1967–1974.
10.
HansenMLSorensenRClausenMT. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med2010; 170: 1433–1441.
11.
Van Loenen, AC. Farmacotherapeutisch Kompas [Pharmacotherapeutic compass], http://www.fk.cvz.nl/ (2010, accessed – 1 Aug 2010).
DienerHCCunhaLForbesC. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci1996; 143: 1–13.
14.
HallasJDallMAndriesA. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: Population based case-control study. BMJ2006; 333: 726–726.
15.
Warlé-Van HerwaardenMFKramersCSturkenboomMC. Targeting outpatient drug safety: Recommendations of the Dutch Harm-wrestling Task Force. Drug Saf2012; 35: 245–259.
16.
The Dutch Institute for Health Care Improvement. Veneuze trombo-embolie en secundaire preventie arteriële trombose [The prevention of venous thromboembolic complications and arterial thrombosis], Utrecht, the Netherlands: CBO, 2009.
17.
SalemDNO'GaraPTMadiasC. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2008; 133: 593S–629S.
18.
BeckerRCMeadeTWBergerPB. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2008; 133: 776S–814S.
19.
BonowROCarabelloBAChatterjeeK. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation2008; 118: e523–e661.
20.
CammAJKirchhofPLipGY. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace2010; 12: 1360–1420.
21.
KushnerFGHandMSmithSCJr. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation2009; 120: 2271–2306.
22.
WijnsWKolhPDanchinN. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J2010; 38: S1–S52.
23.
SilberSAlbertssonPAvilesFF. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J2005; 26: 804–847.
24.
KingSBIIISmithSCJrHirshfeldJWJr. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation2008; 117: 261–295.
25.
AntmanEMHandMArmstrongPW. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation2008; 117: 296–329.
26.
Van de WerfFBaxJBetriuA. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J2008; 29: 2909–2945.
27.
SmithSCJrAllenJBlairSN. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Circulation2006; 113: 2363–2372.
28.
BassandJPHammCWArdissinoD. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J2007; 28: 1598–1660.
29.
VahanianABaumgartnerHBaxJ. Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J2007; 28: 230–268.
30.
AntmanEMAnbeDTArmstrongPW. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation2004; 110: e82–e292.
31.
AndersonJLAdamsCDAntmanEM. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation2007; 116: e148–e304.
32.
SobelMVerhaegheR. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2008; 133: 815S–843S.
33.
GuyattGHCookDJJaeschkeR. Grades of recommendation for antithrombotic agents: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2008; 133: 123S–131S.
34.
ZeymerUJamesSBerkenboomG. Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiolog24 January 2012. [Epub ahead of print].
35.
EisensteinELAnstromKJKongDF. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA2007; 297: 159–168.
36.
NakagawaTHiasaYHosokawaS. The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. J Cardiol2011; 57: 283–289.
37.
MauriLKereiakesDJNormandSL. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J2010; 160: 1035–1041.
38.
O'DonoghueMLBraunwaldEAntmanEM. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet2009; 374: 989–997.
U.S. Food and Drug Administration. Clopidogrel (marketed as Plavix) and omeprazole (marketed as Prilosec) - drug interaction, http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm190848.htm (2009, accessed 17 January 2010).
41.
Warlé-Van Herwaarden MF, Kramers C, Sturkenboom MCJM, et al. Targeting outpatient drug safety: Recommendations of the Dutch Harm-wrestling Task Force. http://www.knmp.nl/downloads/medicijnen-zorgverlening/medicatieveiligheid/harmwrestlingEnglishcopyrightKNMP.pdf (2011, accessed 1 December 2011).
42.
CharlotMGroveELHansenPR. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: Nationwide propensity score matched study. BMJ2011; 342: d2690–d2690.
